Mitsubishi Chemical to sell pharma unit to Bain Capital

Bain Capital to Buy Mitsubishi Chemical’s Pharma Business for More Than $3 Billion
The Japanese chemical company has agreed to sell its pharmaceutical business to Bain Capital for more than $3 billion, in a bid to focus on its key businesses.
Bain throws down $3.3B to acquire Japan's Mitsubishi Tanabe Pharma
Following rumblings of a private equity bidding war late last year, Bain Capital has emer | Bain Capital is laying out 510 billion Japanese yen ($3.3 billion) to acquire Mitsubishi Tanabe Pharma in a carve-out transaction from its parent Mitsubishi Chemical Group.
Bain Is Said to Near $3 Billion Deal for Mitsubishi Pharma Unit
Bain Capital is nearing a deal to buy Mitsubishi Chemical Group Corp.’s pharmaceutical unit, people familiar with the matter said, adding to a dealmaking boom in Japan.
Bain Capital to acquire Tanabe Pharma in a carveout from Mitsubishi Chemical Group
Bain Capital has agreed to acquire Tanabe Pharma, the pharma arm of Mitsubishi Chemical Group Corporation. The deal puts Tanabe Pharma at a valuation of about $3.3 billion. Founded in 1678, Tanabe Pharma is headquartered in Doshomachi, Osaka.
Notice Concerning the Transfer of Mitsubishi Tanabe Pharma Corporation and its Subsidiaries
I Mitsubishi Chemical Group Corporation (MCG) hereby announces that it has resolved, at a meeting of the Board of Directors held today, to
Mitsubishi Chemical to sell drug unit to Bain Capital for $3.3bn
TOKYO -- Japan's Mitsubishi Chemical Group announced on Friday the agreed sale of its pharmaceutical subsidiary, Mitsubishi Tanabe Pharma, to U.S. investment fund Bain Capital for approximately 510 billion yen ($3.36 billion), as it aims to turn around its sluggish core chemical business.
Bain Capital to acquire Japanese pharma giant in $3.3bn deal
Bain Capital entered a deal to acquire Mitsubishi Tanabe Pharma Corporation (MTPC) from Mitsubishi Chemical Group for 510 billion yen ($3.3 billion).
Bain Capital to Acquire Mitsubishi Tanabe Pharma Corporation
Mitsubishi UFJ Morgan Stanley Securities and BofA Securities are serving as financial advisors, and Morrison Foerster, Mori, Hamada & Matsumoto and Ropes & Gray are serving as legal advisors to Bain Capital.
Bain is said to near 500 billion yen deal for Mitsubishi pharma unit
BAIN Capital is nearing a deal to buy Mitsubishi Chemical Group’s pharmaceutical unit, sources familiar with the matter said, adding to a dealmaking boom in Japan. Read more at The Business Times.
Bain to buy Japan's Mitsubishi Tanabe Pharma for $3.4 billion
U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth 510 billion yen ($3.4 billion), saying it was encouraged by prospects of regulatory change for Japan's drug industry.
Bain Capital Nears Acquisition of Mitsubishi’s Pharma Division in $3.2 Billion Deal
Dubai Bain Capital is in the final stages of negotiations to acquire Mitsubishi Chemical Group’s pharmaceutical subsidiary, Mitsubishi Tanabe Pharma, for over 500 billion yen . This move aligns with Mitsubishi Chemical’s strategy to streamline its operations and concentrate on core sectors such as vehicle electrification,
process-worldwide.com1d
Mitsubishi Gas Chemical to Develop H2 Solutions by Methanol Reforming Technology
Mitsubishi Gas Chemical has partnered with Methanol Reformer and Element 1 Corp. to develop as well as commercialize hydrogen ...
Financial Post5d
Mitsubishi Gas Chemical Company, Inc., Methanol Reformer S.L., and Element 1® Corp. Announce Strategic Collaboration
BEND, Ore. — Mitsubishi Gas Chemical Company, Inc. (MGC), a Japanese methanol manufacturer and supplier for chemical and energy sectors including Methanol-to-Hydrogen applications, Methanol ...